--- title: "开达集团发布中期业绩,股东应占亏损 9280.1 万港元,同比增加 22.36%" description: "开达集团发布截至 2025 年 6 月 30 日的中期业绩,报告期内收入为 1.34 亿港元,同比减少 6.14%。股东应占亏损 9280.1 万港元,同比增加 22.36%,每股基本亏损 9.76 港仙。亏损主要因投资物业重估亏绌约 6132 万元。" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/254982061.md" published_at: "2025-08-28T10:55:07.000Z" --- # 开达集团发布中期业绩,股东应占亏损 9280.1 万港元,同比增加 22.36% > 开达集团发布截至 2025 年 6 月 30 日的中期业绩,报告期内收入为 1.34 亿港元,同比减少 6.14%。股东应占亏损 9280.1 万港元,同比增加 22.36%,每股基本亏损 9.76 港仙。亏损主要因投资物业重估亏绌约 6132 万元。 智通财经 APP 讯,开达集团 (00180) 发布截至 2025 年 6 月 30 日止 6 个月的中期业绩,该集团取得收入 1.34 亿港元,同比减少 6.14%;公司权益股东应占亏损 9280.1 万港元,同比增加 22.36%;每股基本亏损 9.76 港仙。 公告称,权益股东应占亏损乃主要归因于投资物业重估亏绌约港币 6132 万元 (截至 2024 年 6 月 30 日止 6 个月:约港币 3178 万元)。 ### Related Stocks - [00180.HK - 开达集团](https://longbridge.com/zh-CN/quote/00180.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Standard Chartered PLC (OTCMKTS:SCBFF) Sees Significant Growth in Short Interest | Standard Chartered PLC (OTCMKTS:SCBFF) experienced a significant increase in short interest, rising 21.1% to 210,583 sha | [Link](https://longbridge.com/zh-CN/news/276119010.md) | | GRAPHIC-Climate Crossroads: A Decade After the Paris Agreement | Ten years post-Paris Agreement, climate data reveals accelerating global warming, with 2025 projected as one of the hott | [Link](https://longbridge.com/zh-CN/news/276053175.md) | | Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/zh-CN/news/276113491.md) | | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) | | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) | --- > **免责声明**:本文内容仅供参考,不构成任何投资建议。